# Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

> **NCT06561087** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 45 (estimated)

## Conditions studied

- Premalignant Lesion

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06561087
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-27
- **Primary completion:** 2027-05-30
- **Final completion:** 2029-05-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561087, "Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06561087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*